Pheno- & Genotyping POF (WHO III)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01411644|
Recruitment Status : Recruiting
First Posted : August 8, 2011
Last Update Posted : May 16, 2017
|Condition or disease|
|Premature Ovarian Failure (POF) Incipient Ovarian Failure Poor Response After Ovarian Hyperstimulation Early Menopause Hypergonadotropic Amenorrhea|
First goal of the study is to phenotype patiens with hypergonadotropic ovarian dysfunction (WHO III) adequately. This group includes women with premature ovarian failure (POF), incipient ovarian failure (IOF), poor response after ovarian hyperstimulation, early menopause and hypergonadotropic primary amenorrhea. The standardized phenotyping consists of a questionnaire focusing on reproductive, medical, and family history; ultrasonography to assess ovarian reserve and/or antral follicle count and obtaining an extra blood sampling during routine endocrine screening for genotyping.
Phenotyping of patients presenting with ovarian dysfunction is of crucial importance when genotyping will be performed. The goal of this genotyping will be the identification of genetic factors associated with the (premature) depletion of the stock of ovarian follicles. It will be performed for isolated WHO III patients in an association (case-control) study for known candidate genes. In familial WHO III cases, genome wide linkage analysis will be performed.
|Study Type :||Observational|
|Estimated Enrollment :||650 participants|
|Official Title:||Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives|
|Study Start Date :||January 2005|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2019|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01411644
|Contact: F. Janse, MD||+31 88 75 55555 ext email@example.com|
|Contact: A. J. Goverde, MD, PhD||+31 88 75 55555 ext firstname.lastname@example.org|
|Utrecht, Netherlands, 3508 GA|
|Contact: F Janse, MD +31 88 755 5555 ext 53629 email@example.com|
|Study Director:||Bart CJ Fauser, MD PhD||UMC Utrecht|